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14-3-314-3-3 reduces cell proliferation by inhibiting the activity of proteins involved in the signaling pathway that
includes Akt kinase. Activation of Akt is enhanced by activating the mammalian target of rapamycin complex
2 (mTORC2). 14-3-3 is also a negative regulator of themTORC2/Akt pathway, by interactingwith a component of
mTORC2. Recently, we reported that selenoprotein W (SelW) regulated the interaction between 14-3-3 and its
target protein, CDC25B. Here,we show that the binding of Rictor, a component ofmTORC2, to 14-3-3, is regulated
by the interaction of 14-3-3 with SelW. When SelWwas down-regulated, mTORC2-dependent phosphorylation
of Akt at Ser473 was decreased. However, the phosphorylation of Thr308 was not affected. The interaction of
Rictor with 14-3-3 was increased in SelW-knockdown cells, as compared to control cells. SelW-knockdown
cells were also more sensitive to DNA damage induced by etoposide, than control cells. This phenomenon was
due to the decreased phosphorylation of Akt at Ser473. We also found that ectopic expression of SelW(U13C)
reduced the interaction between Rictor and 14-3-3, leading to Akt phosphorylation at Ser473. Taken together,
these ﬁndings demonstrate that SelW activates the mTORC2/Akt pathway for Akt phosphorylation at Ser473,
by interrupting the binding of Rictor to 14-3-3.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Selenoprotein W (SelW) is a small selenoprotein (10 kDa) that
contains the selenocysteine (Sec, U) which is encoded by the stop
codon UGA. SelW contains a conserved – CXXU – motif, which corre-
sponds to the – CXXC – motif in thioredoxin (Trx). It may be involved
in cellular redox regulation. SelW is expressed in various tissues [1,2],
and although the precise function of SelW has not been determined, it
is known to have GSH-dependent anti-oxidant activity [3,4]. Further-
more, recovery of the G2/M arrest which was induced by genotoxic
stress was delayed in SelW-knockdown cells because of the sustained
interaction of CDC25B with 14-3-3 [5]. The binding of SelW to 14-3-3
was ﬁrst observed by a NMR study [6].
14-3-3 plays important roles in functionally diverse signaling
processes such as bacterial pathogenesis, neuronal development,
and cell growth control, through its interactions with various binding
partners [7,8]. 14-3-3 is also known to be a negative regulator of cell
proliferation through interactions with its target proteins [9]. For; Rictor, Rapamycin-insensitive
spectroscopy; Trx, thioredoxin;
viation
rights reserved.example, 14-3-3 reduces cell proliferation by inhibiting the activity
of proteins involved in the signaling pathway that includes Akt kinase
[10,11].
Akt is a serine/threonine kinasewhich is involved in various cellular
processes, especially in cell survival [12,13]. Akt is activated by
site-speciﬁc phosphorylation at Thr308 in its T-loop, and Ser473 in its
C-terminal, hydrophobic motif [14,15]. Thr308 is phosphorylated by
3-phosphoinositide-dependent protein kinase 1 (PDK-1) and is
dephosphorylated by protein phosphatase 2A (PP2A) [16,17]. Ser473
is phosphorylated by the mammalian target of rapamycin complex 2
(mTORC2), and the PH domain and leucine-rich repeat protein phos-
phatase (PHLPP) dephosphorylates Akt at this residue [18,19]. 14-3-3 is
a negative regulator of the mTORC2/Akt pathway by interacting with a
component of mTORC2 [11–20].
mTORC2 consists of mTOR, Rictor (rapamycin-insensitive com-
panion of mTOR), mLST8, MAPK-associated protein 1 (Mapkap1/
mSIN1), Protor/PRR5 (protein observed with Rictor) and DEP-domain-
containing mTOR-interacting protein (DEPTOR) [21,22]. Rictor is
required for Akt phosphorylation at Ser473 [23].14-3-3 interacts with
Rictor. Increase of the binding of 14-3-3 to Rictormay reduce the activity
of mTORC2 to phosphorylate Akt at Ser473 [20].
In this study, we found that down-regulation of SelW reduced
cell proliferation and phosphorylation of Akt at Ser473, and that
these occurrences were due to increased binding of Rictor to 14-3-3.
We suggested that SelW regulated the activation of the mTORC2/
Akt pathway by interrupting the interaction between Rictor and
14-3-3.
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2.1. Cell culture, transfection and reagents
Breast carcinoma MCF7 and T47D cells, as well as lung carcinoma
A549 cells were each grown in RPMI 1640 medium containing 10%
fetal bovine serum at 37 °C in 5% CO2. For transient transfections,
MCF7, T47D and A549 cells were seeded at a density of 6 × 105 cells
in 60-mmdishes. Twelve hours after seeding, the cells were transfected
with siRNA using Lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's instructions. To
measure their sensitivity to etoposide, MCF7, T47D and A549 cells
were each treated with 50 μM etoposide (Sigma, St. Louis, MO, USA)
24 h after transfection. The cells were then harvested as described in
the ﬁgure legends.
2.2. RNA interference and plasmids
The siSelWs used in this study were designed by Invitrogen. The
three sequences for human siSelW were as follows: siSelW 1, 5′-CCA
CCG GGU UCU UUG AAG UGA UGG U-3′; siSelW 2, 5′-GGA AGU UGA
UUC ACU CUA AGA AGA A-3′; and siSelW 3, 5′-UCU GAA GUU GGU
GGC CGC CAU CAA A-3′. A point mutation in SelW at Sec13 to Cys was
generated by site-directed mutagenesis of the cDNA by polymerase
chain reaction (PCR) using the pcDNA 3.1+/SelW plasmid [3]. The
HA-14-3-3β plasmid was provided [5].
2.3. Antibodies and western blotting
The proteins of whole-cell lysates were separated by SDS-PAGE, and
the separated proteins were then transferred to a membrane and
probed with speciﬁc antibodies. Antibodies were obtained from the fol-
lowing sources: anti-Akt, anti-phospho-Akt (Ser473), anti-Rictor and
anti-cleaved poly (ADP-ribose) polymerase (PARP) antibodies were
from Cell Signaling (Danvers, MA, USA); anti-phospho-Akt (Thr308)
and anti-p27 antibodies were from Santa Cruz Biotech (Santa Cruz,
CA, USA); anti-His and anti-HA antibodies were from ABM (Richmond,
BC, Canada); anti-α-tubulin (AB Frontier, Daejeon, Korea). To detect
SelW, the cell lysates were incubated with LDS sample buffer and re-
ducing reagent (Invitrogen) at 70 °C for 10 min. The lysates were then
separated in a 12% Bis-Tris gel (Invitrogen), transferred to a membrane
and probed with the SelW antibody [5].
2.4. RNA isolation and RT-PCR
For RT-PCR of SelW, total RNA was isolated from MCF7 cells using
TRIzol reagent (Invitrogen). We carried out PCRs in a ﬁnal volume of
50 μl containing SuperScriptase™ III reverse transcriptase and oligo (dT)
(Invitrogen). We ampliﬁed all of the sequences with multiple cycles
(20–28 cycles). RT-PCR primers for gene sequences were designed
between different exons to prevent ampliﬁcation of DNA. The following
forward and reverse primerswere used: for SelW, 5′-GAGGCTACAAGT
CCA AGT ATC TTC A-3′ and 5′-CAT CAG GGA AAG ACC AGG TG-3′;
GAPDH, 5′-AGG TCG GAG TCA ACG GAT TT-3′ and 5′-AGG TGG AGG
AGT GGG TGT CG-3′ [24]. The PCR products were resolved in a 2%
agarose gel andwere subsequently visualized by stainingwith ethidium
bromide.
2.5. Immunoprecipitation
For immunoprecipitation, lysates were mixed with antibodies
overnight, and the immune complexes were then incubated with pro-
tein A or G beads for 1.5 h. The beads were washed and boiled with
2× SDS sample buffer for 3 min. The samples were loaded onto
SDS-PAGE gels, transferred to a membrane, and were then incubated
with primary antibody at 4 °C for overnight. After further incubationwith HRP-conjugated secondary antibody for 1 h at room temperature,
immunoreactive bands were visualized using a West Pico enhanced
ECL detection kit (Pierce), and the intensity was determined
densitometrically using ImageJ software.
2.6. MTT assay
The proliferation of MCF7 cells was determined by MTT assay. The
cells were transiently transfected with siControl or siSelW. Twenty-four
hours after transfection, the media were replaced with the same media
containing 0–20% serum for 48 h. The media were then replaced with
media containing 5 mg/ml of MTT for 2 h at 37 °C. After incubation,
100 ml of dimethyl sulfoxide (DMSO) was added to dissolve the insol-
uble product into a colored solution. The absorbance of the solution at
570 nm was determined using an automated microplate reader.
2.7. Wound-healing assay
Twelve hours after seeding, MCF7 cells were transfected with
siControl or siSelWby electroporation using a Neon transfection system
(Invitrogen). After transfection, the cells in medium containing 10% FBS
were seeded at a density of 5 × 106 cells in 60-mmdishes. Twenty-four
hours after seeding, the conﬂuent monolayer was scratched using
200 μl yellow pipette tips. The percentage of closed wound was mea-
sured by calculating the average distance between the two wound
edges and the migration length [25].
2.8. Flow cytometry
MCF7 cells were transiently transfected with siControl or siSelW.
At 6 h after transfection, the cells were subsequently incubated with
2.5 mM thymidine for 18 h. After release from the thymidine block,
the cells were harvested at the indicated times. For cell cycle analysis,
MCF7 cells were ﬁxed overnight in ice-cold 70% ethanol. The cells
were then collected by centrifugation and resuspended in PBS.
Resuspended cells were treated with RNaseA (50 μg/ml) for 30 min at
RT, and the cells were then stained with propidium iodide (50 μg/ml).
Subsequently, the cell cycle distributionwas analyzedusing a FACSCalibur
ﬂow cytometer (BD Bioscience, San Jose, CA, USA).
2.9. Colony formation
After MCF7 cells were transfected with 50 pmol of siControl or
siSelW by electroporation using a Neon transfection system (Invitrogen),
the cells were seeded at a density of 2 × 103 cells in 60-mm dishes. The
cells were incubated for 24 h, and then treated with 0–20 μM of
etoposide. After 10 days, the dishes were stained with MTT reagent,
stained colonies were counted, and the degree of colony formation
relative to that of the control was determined. A colony was deﬁned
as a cluster of at least 50 cells.
3. Results
3.1. The effect of SelW on cell proliferation
Down-regulation of SelW caused cell cycle arrest and increased
the levels of cell cycle arrest-related proteins [26]. We previously
reported that SelW-knockdown slowed down cell cycle progression
in NIH3T3 and MCF7 cells [5]. In this study, we investigated whether
SelW was involved in the cell proliferation of MCF7 cells. We intro-
duced three independent siRNAs against SelW into cells as described
in the Materials and methods. Fig. 1A and B shows that the expression
of SelW mRNA was efﬁciently reduced by all siRNAs in MCF7 cells for
72 h. We also determined through a wound-healing assay that SelW
was involved in cell proliferation. Thus, the cell proliferation of
SelW-knockdown MCF7 cells was decreased compared to that of
Fig. 1. Cell proliferation is decreased in SelW-knockdown MCF7 cells. MCF7 cells were transiently transfected with siControl or siSelW. (A) Cells were harvested 24 h after trans-
fection with three independent siSelWs. The mRNA of SelW was subsequently analyzed by RT-PCR. siSelW pools are a mixture of three siSelWs. GAPDH served as a loading control.
(B) The mRNA of SelW was analyzed by RT-PCR to detect the effect of siRNAs for 72 h. GAPDH served as a loading control. (C) The proliferation of MCF7 cells was measured using
the wound-healing assay, as described in the Materials and methods. The images were captured at the indicated times after wounding. Bar: 100 μM (left). The quantity of migrated
cells represents the average values at the indicated times (right). (D) The rate of proliferation was measured using the MTT assay. Twenty-four hours after transfection, the media
were replaced with the same media containing 0–20% serum for 48 h. (E) The ﬂow cytometry assay was performed as described in the Materials and methods. After release from
the thymidine block, the DNA content was analyzed by FACS analysis at the indicated times. The graph indicates the results from three independent experiments (**p b 0.001,
*p b 0.05). Error bars in the graph represent ± standard deviation (s.d.), and the p value compares the siControl to siSelW.
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distance between the invading front of the cells in randomly selected
microscopic ﬁelds at the indicated times, and the degree of prolifera-
tion was expressed as the percentage of closure of the original wound
width (Fig. 1C). It has been known that increasing amounts of serum
enhanced the proliferation rate of most cell types in a concentration-
dependent manner [27]. However, the proliferation rate of SelW-
knockdown cells was not enhanced as much as that of control cells
in a serum concentration-dependent manner, as shown in Fig. 1D.
We also detected that cell cycle progression was arrested at the
G1-phase in SelW-knockdown MCF7 cells (Fig. 1E). These results in-
dicate that SelW may be involved in the signal mechanism of cell
proliferation.
3.2. The effect of SelW on Akt phosphorylation and cell viability
The signaling pathway involving Akt is activated during cell prolifer-
ation and survival [12]. It has also been reported that aberrant Akt acti-
vation caused tumorigenesis in breast and lung [28,29]. To understand
the regulatory effect of SelW on cell proliferation, we determined the
Akt phosphorylation status of MCF7, T47D, and A549 cell lines which
have activated Akt. The MCF7 cell line was often used for the study of
SelW function [30], and we suggested that down-regulation of SelW
increased the sensitivity against genotoxic stress using the MCF7 andA549 [5]. We observed that the mRNA level of SelW in T47D breast
cancer cell line was six-fold higher than that of MCF10A normal breast
cell line by real time PCR analysis (data not shown). Phosphorylation
of Akt at Ser473 was reduced after down-regulation of SelW, whereas,
Thr308 phosphorylation was not affected, as shown in Fig. 2. The level
of p27 protein was increased in SelW-knockdown cells compared to
control cells (Fig. 2). The level of p27 might be increased by decrease
of Akt phosphorylation at Ser473. It was suggested that activation of
Akt reduced the expression level of p27 protein, which resulted in un-
controlled cell proliferation in various cancer cells [31]. Next, we deter-
mined the sensitivity of the cells to the anti-cancer drug etoposide,
which is known to be a topoisomerase II inhibitor and to induce cell
cycle arrest [32,33]. To do this,MCF7, T47Dor A549 cellswere transient-
ly transfected with siControl or siSelW and were then treated with the
reagent as described in the upper panel of Fig. 3A. The phosphorylation
level of Akt at Ser473was lower in all SelW-knockdown cells compared
to control cells after etoposide treatment, whereas phosphorylation at
Thr308 was not altered. We also found that the PARP was rapidly
cleaved in SelW-knockdown cells compared to control cells (Fig. 3A).
These results indicate that the down-regulation of SelW made cells
more sensitive to etoposide. The enhanced sensitivity of SelW-
knockdown cells was also conﬁrmed by colony formation assay. Colony
formation of SelW-knockdown MCF7 cells was much less than that of
control cells, and the number of colonies was reduced by etoposide
Fig. 2. Akt phosphorylation at Ser473 is decreased in the down-regulation of SelW. MCF7, T47D or A549 cells were transiently transfected with siControl or siSelW. The cells were
harvested 24 h after transfection and were then analyzed by western blot using the indicated antibodies. α-Tubulin served as a loading control.
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when SelW-knockdown MCF7 cells were treated with etoposide, the
subG1 population was much larger than that of control cells (Fig. 3C).
These results indicate that the down-regulation of SelW reduces the
phosphorylation of Akt at Ser473 and cell viability after treatment with
etoposide.Fig. 3. SelW-knockdown cells increase the sensitivity to etoposide. MCF7, T47D or A549 ce
described (top). Twenty-four hours after transfection, the cells were treated with 50 μM etopo
blot using the indicated antibodies. α-Tubulin served as a loading control. (B) For colony form
transfection, the cells were cultured for 10 days and were then stained with MTT. (C) The MC
then analyzed by FACS at the indicated times, and data were obtained using the CellQuestPro
iments (**p b 0.001, *p b 0.05). Error bars in the graph represent ± standard deviation (s.d.),3.3. Binding of SelW to 14-3-3 affects mTORC2 activity
To understand the regulatory mechanism of SelW in Akt phos-
phorylation, we expressed a mutant SelW where Sec was changed
to Cys (U13C). Expression of recombinant wild type SelW was very
difﬁcult to work with, as the codon for Sec, UGA, was often recognizedlls were transiently transfected with siControl or siSelW. (A) The experimental plan is
side. The cells were harvested at the indicated times and were then analyzed by western
ation analysis, MCF7 cells were treated as described in the Materials and methods. After
F7 cells in (A) were harvested at the indicated times. The subG1 population of cells was
program (BD Biosciences). The graph indicates the results from three independent exper-
and the p value compares the siControl to siSelW.
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replaced with a Cys (U13C). Although SelWmodulated the phosphor-
ylation of Akt at Ser473, it did not interact with Akt in normal or
DNA-damage conditions (Fig. 4A). To investigate how the phosphor-
ylation of Akt at Ser473 was reduced by the down-regulation of
SelW, we analyzed the regulatory pathway of Akt phosphorylation at
Ser473. It has been reported that 14-3-3 reduced the phosphorylation
of Akt at Ser473 [10], and so, we measured the Akt phosphorylation at
Ser473 in HA-14-3-3β overexpressing MCF7 cells. Phosphorylation of
Akt at Ser473 was signiﬁcantly decreased by 14-3-3, whereas phos-
phorylation at Thr308 was not altered (Fig. 4B). We determined an in-
teraction of SelW with 14-3-3 (Fig. 4C), and that Akt phosphorylation
at Ser473 was enhanced by increased binding of SelW to 14-3-3
(Fig. 4D). Recently, we reported that the activity of a 14-3-3 binding
protein was regulated by the interaction of SelW with 14-3-3 in
NIH3T3 cells [5].
Akt at Ser473 is phosphorylated by mTORC2, the activity of which
is regulated by complex formation between Rictor and 14-3-3
[11–20]. Therefore, we investigated whether SelW was involved in
the phosphorylation of Akt at Ser473 by regulating this complex for-
mation between Rictor and 14-3-3. We found that the binding of
Rictor to 14-3-3 was signiﬁcantly increased in SelW-knockdownFig. 4. Phosphorylation Akt at Ser473 is enhanced by the binding of SelW to 14-3-3. (A) M
Materials and methods. Twenty-four hours after transfection, the cells were treated with
and cell extracts were immunoprecipitated with either anti-Akt or anti-Rabbit IgG antibodi
with empty vector or HA-14-3-3β. The cells were harvested 24 h after transfection and we
loading control. (C) MCF7 cells were co-transfected with His-SelW(U13C) or HA-14
immunoprecipitated with either anti-His or anti-Mouse IgG antibodies and were then im
MCF7 cells in (C) were treated with 50 μM of etoposide. After treatment, the cells were harv
during DNA damage induced by etoposide, and were then immunoblotted using the indicaMCF7, T47D and A549 cells compared to control cells, either in the
presence or absence of etoposide (Fig. 5A and B). Although SelW
was involved in the activation of mTORC2, Rictor was not interacted
with SelW (Fig. 5C). However, the overexpression of SelW(U13C)
reduced the binding of Rictor to 14-3-3 and increased phosphorylation
of Akt at Ser473 (Fig. 5D). These results indicate that SelW plays a key
role in the phosphorylation of Akt at Ser473 by interrupting the interac-
tion between Rictor and 14-3-3. Fig. 5E shows a schematic illustration of
how SelW regulates the mTORC2/Akt pathway.
4. Discussion
It was suggested that SelW regulates proteins involved in cell
cycle progression and is required for recovery from G2 arrest induced
by genotoxic stresses [5–30]. Down-regulation of SelW delayed cell
cycle progression at the G1/S transition [24], and caused G1 arrest
by increasing the level of MKK4 [34]. Additionally, mRNA of SelW
was reduced during S-phase [24]. In this study, we found that the
down-regulation of SelW retarded cell cycle progression (Fig. 1C, D
and E). These results suggested that SelW might regulate cell cycles
in various mechanisms, although the mechanism was not clear. Our
previous work showed that the down-regulation of SelW inactivatedCF7 cells were transfected with empty vector or His-SelW(U13C), as described in the
or without 50 μM of etoposide. The cells were then harvested 24 h after treatment,
es and immunoblotted using the indicated antibodies. (B) MCF7 cells were transfected
re then analyzed by western blot using the indicated antibodies. α-Tubulin served as a
-3-3β, and the cells were harvested 24 h after transfection. Cell extracts were
munoblotted with anti-HA antibody. (D) Twenty-four hours after transfection, the
ested at the indicated times. Cell extracts were immunoprecipitated with His antibody
ted antibodies.
Fig. 5. Binding of SelW to 14-3-3 affects mTORC2 activity. (A) MCF7, T47D and A549 cells were co-transfected with siControl or siSelW and HA-14-3-3β. The cells were harvested
24 h after transfection, and were then immunoprecipitated with anti-Rictor antibody, and immunoblotted with anti-HA antibody. (B) The MCF7 cells in Fig. 3A were harvested at
the indicated times, and were then immunoprecipitated with anti-14-3-3, and immunoblotted with anti-Rictor antibody. (C) MCF7 cells were transfected with empty vector or
His-SelW(U13C). The cells were harvested 24 h after transfection and were then immunoprecipitated with anti-His antibody and immunoblotted with anti-Rictor antibody. (D) The
MCF7 cells in (C) were immunoprecipitated with anti-14-3-3 antibody and were then immunoblotted using the indicated antibodies. (E) Model for the role of SelW in the regulation
of the mTORC2/Akt pathway.
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NIH3T3 cells [5]. p21 and p27 are involved in cell cycle arrest [35–37],
and the expression of p21 is transcriptionally regulated by p53 [38].
However, p27 is not regulated by p53 [26]. The expression of p27 is
mainly regulated by its rate of degradation, rather than by transcrip-
tional control [39]. Degradation of p27 occurs when the protein is
phosphorylated at Thr157 by Akt [40]. As shown in Fig. 2, the down-
regulation of SelW decreased Akt phosphorylation and increased the
protein level of p27 (Fig. 2). Decreased Akt phosphorylation at Ser473
by down-regulation of SelW might cause an increased protein level of
p27.
Many studies have found that Akt is involved in various cellular
processes, including cell proliferation and survival, and its activity is
increased in a wide variety of cancers [12,13]. It is also known that
14-3-3 reduces the phosphorylation of Akt at Ser473, which results
in the inactivation of Akt, and inhibits Akt-mediated tumorigenicity
in cancer cells [10]. We observed that the down-regulation of SelWreduced Akt phosphorylation at Ser473, whereas Thr308 phosphoryla-
tionwas not affected inMCF7, T47D or A549 cells (Fig. 2). The phenom-
enon is consistent with SelW being upstream of Akt phosphorylation at
Ser473. It was reported that Akt was activated as a means of protecting
cells from anti-cancer drugs. Activation of Akt protects cells from
etoposide-mediated apoptotic cell death [41], whereas inactivation of
Akt decreases cell proliferation and increases sensitivity to anti-cancer
drugs [42,43]. To address the role of SelW in sensitivity to anti-cancer
drugs, we treated cells with etoposide.We found that Akt phosphoryla-
tion at Ser473 was increased to protect cells treated with etoposide at
the early stage, but not SelW-knockdown cells. Down-regulation of
SelW increased cell sensitivity to DNA damage induced by etoposide,
due to decreased phosphorylation of Akt at Ser473, and increased
cleaved PARP (Fig. 3A).
Increased sensitivity to etoposide in SelW-knockdown cells was
further conﬁrmed through observations of colony formation. We
found that the number of colonies in SelW-knockdown cells was
2141Y.H. Jeon et al. / Biochimica et Biophysica Acta 1833 (2013) 2135–2142reduced compared to that in control cells treated with various con-
centration of etoposide (Fig. 3B). SelW-knockdown cells clearly
formed fewer colonies compared to control cells without etoposide
treatment, because down-regulation of SelW caused cell cycle arrest,
which resulted in the reduction of cell proliferation (Fig. 1E). The
observation that down-regulation of SelW reduced phosphorylation
of Akt at Ser473 is very intriguing, although SelW did not interact
with Akt (Fig. 4A), it is possible that SelWmay be an appropriate target
for therapy in Akt-activated cancer.
mTOR is a conserved Ser/Thr kinase that forms two functionally
dissimilar complexes, mTORC1 and mTORC2. These complexes are in-
volved inwidespread processes, including cell proliferation and survival.
mTORC2 activity is required for phosphorylation of Akt at Ser473 [21,22],
and facilitates Thr308 phosphorylation by PDK1 [23]. Many types
of cancer of human malignancy are associated with a dysregulated
mTORC2/Akt pathway. Moreover, targeting of mTORC2, but not
mTORC1 prevents cell migration and promotes apoptosis induced by
anti-cancer drugs [44,45]. Therefore, the mTORC2/Akt pathway is an
important therapeutic target. A study showed that S6K1-mediated
phosphorylation of Rictor at Thr1135 negatively regulated the ability
of mTORC2 to phosphorylate Akt at Ser473. Phosphorylation of Rictor
at Thr1135 within mTORC2 stimulates binding of Rictor to 14-3-3. The
phosphorylation of Rictor at Thr1135 did not affect the substrates of
mTORC2 other than Akt [11]. Therefore, 14-3-3 may be an appropriate
target for cancer therapy, as a cellular inhibitor of Akt. We found that
Akt phosphorylation at Ser473 was enhanced by increasing binding of
SelW to 14-3-3 (Fig. 4D), and that the interaction between Rictor and
14-3-3 was increased in SelW-knockdown cells (Fig. 5A and B). The in-
teraction between Rictor and 14-3-3was reduced by ectopic expression
of SelW(U13C) (Fig. 5D). Therefore, our ﬁndings suggest that SelW reg-
ulates mTORC2-mediated phosphorylation of Akt at Ser473.
Intriguingly, we found that the binding of Rictor to 14-3-3 was
clearly inhibited by the interaction of SelW with 14-3-3, which
maintained the activity of Akt. However, we cannot rule out that com-
ponents of mTORC2 other than Rictor may also be regulated by SelW.
Because 14-3-3 has widespread roles through its interactions with var-
ious signaling pathway proteins, SelW may be involved in regulating
the association of 14-3-3 with many other target proteins. The general
mechanism of regulating this association remains to be elucidated.
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